The European Myeloma Network

A non-profit organisation created to increase understanding of multiple myeloma and to produce effective research projects and clinical trials.

Read more

Development

Measurable residual disease (MRD)

The most widely used tests are flow cytometry, polymerase chain reaction (PCR) and next-generation sequencing (NGS). These tests use samples of bone marrow cells (taken by aspiration) and/or peripheral blood cells (taken through a vein).

Read more

Clinical trials

EMN-COVID view

EMN29 view

EMN27 view

EMN26 view


View all

About the HARMONY Alliance

Accelerating Better and Faster Treatment for Patients with Hematologic Malignancies.

The HARMONY Alliance is a Public-Private Partnership for Big Data in Hematology including over 100 organizations such as European medical associations, hospitals, research institutes, patient organizations, pharmaceutical and IT companies. HARMONY uses Big Data analytics to accelerate the development of more effective treatments for blood cancer patients. Various groups participate in HARMONY, including EMN. HARMONY Research Project Leads and Key Opinion Leaders in Multiple Myeloma are Prof. Pieter Sonneveld, Prof. Mario Boccadoro, and Prof. Jesus San-Miguel.

Read more

About EMN

Multiple Myeloma

Multiple myeloma is a rare and highly heterogeneous hematologic
malignancy, and the clinical research certainly plays a fundamental role in
the management of patients with this disease.

 

To deal with such a complex scenario, in 2005, a group of European
hematologists pulled together to increase their understanding of multiple
myeloma and to produce effective research projects and clinical trials.
These efforts resulted in the creation of the European Myeloma Network
(EMN), a non profit organization.

Read more

Participating centers

Over 180 centers divided between 21 countries are part of EMN.

View locations

Guidelines

Various reviews, guidelines and recommendation papers are produced under the EMN umbrella. To collect & better coordinate the various proposals and manuscripts, a guideline team is in place: Monika Engelhardt from Germany, Niels van de Donk from the Netherlands, Francesca Gay from Italy and Evangelos Terpos from Greece.

Read more

Diversity and inclusion

Inclusion is a major value for the EMN, particularly when it comes to clinical trials. The myeloma community is in fact highly heterogeneous and the EMN strongly believes that the same high-quality treatments should be offered to any patients, regardless of their gender, race, ethnicity, sexualorientation, disability, religion, age, cultural backgrounds, life experiences, thoughts, and ideas. We are extremely grateful for the fundamental role our patients play in the EMN clinical studies, and the contribution of each one of them is equally recognized and appreciated.

Pieter Sonneveld

President

Mario Boccadoro

Vicepresident

Fredrik Schjesvold

Senior

Gordon Cook

Senior

Heinz Ludwig

Senior

Hermann Einsele

Senior

Jesus San-Miguel

Senior

Meletios Dimopoulos

Senior

Philippe Moreau

Senior

Roman Hajek

Senior

Annemiek Broijl

President - Junior

Cyrille Touzeau

Junior

Enrique Ocio

Junior

Francesca Gay

Junior

Guldane Cengiz Seval

Junior

Jakub Radocha

Junior

Leo Rasche

Junior

Maria Gavriatopoulou

Junior

Maria Krauth

Junior

Rakesh Popat

Junior

Tobias Slordahl

Junior

News

23 June 2022

Congratulations to our EMN President! read

30 March 2022

EMN29 approval in Spain and the USA read

Events

20 April 2022

4th EMN meeting 20-23 April 2023 – save the date! view

06 October 2021

14th EMN Trialist Forum 2-3 October 2022 – save the date! view

Contact

For more information about our trials or events, you can contact us through: info@emn.life

Although we do understand sometimes it is hard to navigate the complex world of multiple myeloma, we cannot provide clinical assessments or consultations by email. Please refer to your treating physicians for any doubts, they certainly have a more complete overview of your medical history and treatments to appropriately assist you.